These findings therefore suggest that DDR1 and DDR2 determine BRAF mutant melanoma cell responsiveness to BRAF‐targeted therapy, with regard to ECM features and that the drug‐tolerant action of DDR is dependent on their enzymatic activities and correlates with the formation of filamentous membrane structures. The gene discussed is BRAF; the disease is melanoma.